MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL

(1:21)

MRD dynamics in multiple myeloma: current approaches and unanswered questions

(1:47)

Prognostic value of evaluating MRD dynamics in multiple myeloma maintenance

(18:24)

Using MRD to improve prognostication during the maintenance phase of myeloma treatment

(1:25)

Insights Discovery and MRD

(2:11)

Minimal Residual Disease (MRD)

(3:7)

What is MRD, or Minimal Residual Disease?

(3:44)

ctDNA and MRD—How, When, and on Who Do We Use It | Kristen Ciombor, MD | ESMO22 Pennsylvania

(2:3)

MRD \u0026 Me

(8:18)

Ths six factors of high performing teams from M R Dynamics

(3:9)

Measuring MRD: methods and challenges

(2:2)

The emerging role of MRD in colorectal cancer decision making

(2:53)

The role of MRD in ALL: what defines a complete response?

(3:35)

Is MRD Negativity the Goal of Myeloma Treatment?

(1:2:7)

MRD measurement: next-generation sequencing or flow cytometry?

(41)

Future Directions for MRD Testing in ALL

(4:8)

Significance of Minimal Residual Disease in Acute Myeloid Leukemia

(58:32)

MRD in myeloma: the FDA perspective

(1:26)